+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 68 Actively Recruiting clinical trials

O

Actively Recruiting

This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.

Age: 18Years - 100YearsAll Genders
141 locations
O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of chemotherapy treatments in adults diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN. This observational study aims to provide comparative data to the ELZONRIS registry study by reviewing real-world outcomes of patients treated with various chemotherapy regimens as their first-line therapy since May 2016. Participants have received chemotherapy regimens similar to those used for acute myeloid leukemia, acute lymphocytic leukemia, or lymphoma, with choices made by their healthcare providers based on institutional practices. No study medication is provided by the sponsor. The study collects data retrospectively without administering new treatments. During the study, researchers collect information on response rates, duration of response, progression-free and overall survival, adverse events, transfusion needs, treatment durations, hospitalization details, and transitions to stem cell transplant. Data is gathered from the start of treatment through up to 26 months, offering insights into treatment patterns and outcomes. Participants privacy and consent are managed following local regulations.

Age: 18Years +All Genders
67 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
C

Actively Recruiting

Researchers are evaluating treatments for adults with high risk chronic lymphocytic leukemia CLL, a common and aggressive form of leukemia. The study compares a triple drug combination of acalabrutinib, obinutuzumab, and venetoclax GAVe against a dual combination of obinutuzumab and venetoclax GVe. This phase 3 trial aims to see if adding acalabrutinib can prolong the time patients live without disease progression, focusing on patients with specific genetic risk factors like 17p deletion, TP53 mutation, or complex karyotype. Participants receive infusions of obinutuzumab on specific days during the first six cycles, along with oral venetoclax taken daily with increasing doses during the initial cycles and then a fixed dose for up to 12 cycles. Those in the triple combination group also take oral acalabrutinib twice daily for cycles 15 to 24. Treatments are given in cycles lasting several weeks, with precise dosing schedules for each medication. During the study, participants undergo regular assessments including blood tests to monitor disease status and treatment effects. Researchers measure progression-free survival as the primary outcome, along with other outcomes such as minimal residual disease, overall response, survival rates, and time until next treatment. The study involves randomized assignment to treatment groups and continues through multiple cycles, with monitoring extending up to 50 months after the first patient is included.

Age: 18Years - 120YearsAll GendersPhase 3
30 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
O

Actively Recruiting

Researchers are studying the clinical and health outcomes of amivantamab-containing treatments for people with common EGFR-mutated advanced non-small cell lung cancer NSCLC. NSCLC is the most common type of lung cancer and can spread to other parts of the body. This observational study looks at how these treatments work in real-world clinical settings for patients with specific EGFR mutations. Participants include those with advanced NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations. Two groups are observed one receiving amivantamab combined with carboplatin and pemetrexed after previous therapy failure, and another receiving amivantamab with lazertinib as first-line treatment. No study drugs are provided data is collected from routine medical care. During the study, researchers collect data on treatment duration, progression-free survival, overall survival, adverse events, dose changes, and medication use for up to about 60 months. Quality of life is assessed using the SKINDEX and EORTC QLQ-C30 questionnaires. The study tracks how patients respond to treatment and monitors safety outcomes, with participation lasting several years.

Age: 18Years +All Genders
90 locations
E

Actively Recruiting

Researchers are evaluating the effects of the medicine imlunestrant LY3484356 on premenopausal women with early estrogen receptor-positive, HER2-negative breast cancer. The study includes two groups one to compare imlunestrant with and without ovarian suppression against tamoxifen over up to 29 days, and another to assess imlunestrants effects on the ovaries compared to tamoxifen over up to 6 months. This phase 2 trial aims to understand treatment impacts on breast cancer cells and ovarian function. Participants receive different treatments depending on their group in Cohort 1, some take imlunestrant orally alone, some take it with subcutaneous goserelin to suppress ovarian function, and others take oral tamoxifen. In Cohort 2, participants take either oral imlunestrant or oral tamoxifen without ovarian suppression. Treatments last up to 29 days for Cohort 1 and up to 6 months for Cohort 2. During the study, participants will provide tumor samples before and during treatment, and researchers will monitor tumor markers such as Ki-67, estrogen receptor, and progesterone receptor expression. They will also track ovarian cysts over 180 days. The study includes assessments of organ function and performance status, with participant involvement lasting up to 6 months depending on the cohort.

Age: 18Years +FEMALEPhase 2
90 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the combination of KarXT and KarX-EC for cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3, randomized, double-blind, placebo-controlled study aims to understand how these treatments impact cognitive function and overall condition in this patient group. Participants will be randomly assigned to receive either KarXT plus KarX-EC or a placebo, with specified doses given on specific days. The treatment period lasts 24 weeks, during which participants will be monitored closely to assess changes in cognition and daily functioning. Throughout the 24 weeks, participants will undergo evaluations including cognitive tests like the Alzheimers Disease Assessment Scale-Cognitive Subscale 11 and the Clinicians Interview-Based Impression plus Caregiver Input. Researchers will also track safety through monitoring adverse events, vital signs, lab tests, and other clinical assessments to understand the treatments impact and safety profile.

Age: 60Years - 85YearsAll GendersPhase 3
119 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations

1-10 of 68

1